Stroke recovery trial pulled before it even started
NCT ID NCT05367362
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test whether adding the antibiotic minocycline to standard stroke treatment could improve recovery in people who had a severe stroke. It was designed as a small, early-phase trial with about 40 participants, but it was withdrawn before enrolling anyone. Because no data were collected, we don't know if minocycline would have helped or not.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Minocycline (an antibiotic that may also protect brain cells)
- What this could lead to
- If it had worked, this could have pointed toward a simple add-on treatment to improve recovery after a severe stroke.
- What could go wrong
- The trial was withdrawn before any patients were enrolled, so we have no results. Even if it had run, it was a small, early-phase study, so success was far from guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Started
-
Dec 2025
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. provision of consent, either by self or authorized representative, willingness and ability to participate in study procedures 2. Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia 3. Age more than 18 years 4. Premorbid Rankin score ≤ 3 5. Treatment with intra-arterial endovascular revascularization methods. 6. Patients should be given first dose of minocycline as soon as possible, latest by 24 hours after the endovascular stroke intervention Exclusion Criteria: 1. Allergy/ Intolerance to tetracycline antibiotics 2. Pregnant women - positive pregnancy test on admission or known to be pregnant 3. ALT or AST \> 3 times the upper limit of normal 4. Serum creatinine \> 2 mg/dL 5. Patient is participating in another clinical trial at any time during the duration of the study that could confound the treatment or outcomes of this investigation; and/or 6. Has a severe health condition that may potentially result in death within 6 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a kidney protein drug boost stroke recovery after clot removal?
- Can PET scans reveal hidden heart inflammation after a stroke?
- Can an implanted heart monitor catch hidden irregular heartbeats after stroke?
- China builds national watchdog for brain blood vessel devices
- Cancer patients face a hidden Second-Stroke threat, and 24 hospitals are mapping it
- Can tiny neural exosomes help the brain heal after a severe stroke?